Please login to the form below

Not currently logged in
Email:
Password:

Zantac

This page shows the latest Zantac news and features for those working in and with pharma, biotech and healthcare.

Perrigo expands consumer health with €3.6bn Omega purchase

Perrigo expands consumer health with €3.6bn Omega purchase

Belgium-based Omega has also expanded in recent years purchasing several over-the-counter (OTC) medicines from GlaxoSmithKline (GSK) in 2012, including Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase.

Latest news

  • GSK plans to sell off older products GSK plans to sell off older products

    Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established

  • Boehringer creates ‘Captain Zantac’ Boehringer creates ‘Captain Zantac

    Boehringer creates ‘ Captain Zantac’. Animated fireman fronts marketing campaign in US for heartburn remedy. ... Zantac has been a leader in heartburn relief for more than two decades.

  • GSK sells Lucozade and Ribena for £1.35bn GSK sells Lucozade and Ribena for £1.35bn

    This was followed in March 2012 by the sale to Belgian company Omega of brands such as Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase for £391m and then a month later

  • Boehringer names Ross Ullman as US consumer marketing director

    Boehringer names Ross Ullman as US consumer marketing director. His responsibilities will include developing the Zantac and Dulcolax brand visions. ... Through his vision and past successes, we are confident that Ross can help take Zantac and

  • Pfizer sells nutrition unit to Nestle, as GSK offloads more OTC

    It will sell a set of brands that includes Phillips MOM, Solpadeine, Dequadin, Cartia and Zantac with annual sales of around £60m ($97m) to Aspen Pharmacare for £164m ($265m) in cash. ... The deal is expected to close in the second quarter. Last month,

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Interview: Laure Thibaud, Sanofi Interview: Laure Thibaud, Sanofi

    It was also the dawn of the industry's blockbuster era, which for Glaxo meant the years of its star-performing indigestion and heartburn treatment Zantac.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics